Abstract: A method of treating a disease of condition administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage comprising a therapeutically effective amount of a drug to treat said disease or condition and a form of hyaluronic acid characterized in that the composition is immediately available to transport the drug percutaneously into the epidermis of the skin or exposed tissue to the site of trauma or pathology of the disease or condition to be treated.

Abstract: The invention relates to a method of rapidly transporting a drug to the epidermis and accumulating and maintaining the drug therein for a prolonged period of time comprising administration of a therapeutically efective non-toxic amount of the drug with an effective amount of hyaluronic acid.

Abstract: A method of treating a disease or condition comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage comprising a therapeutically effective amount of a drug to treat said disease or condition and a form of hyaluronic acid characterized in that the composition is immediately available to transport the drug percutaneously into the epidermis of the skin or exposed tissue to the site of trauma or pathology of the disease or condition to be treated.

Abstract: Topically applied transdermally quick penetrating (best targeting the epidermis and subsequently remaining there for a prolonged period of time) systemic independent acting, combinations and formulations which employ, combine, or incorporate a therapeutically effective non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis together with an amount of hyaluronic acid and/or salts thereof (for example the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub units of hyaluronic acid to treat a disease and condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (

Abstract: A method of accumulating a drug and a form of hyaluronic acid in the skin and/or exposed tissue of a human includes topically administering a therapeutically effective dosage amount of a formulation which comprises at least 5 mg/cm.sup.2 of the form of hyaluronic acid and a therapeutically effective amount of the drug.

Abstract: A method is provided of inhibiting the narrowing of the vascular tubular walls of an animal by the proliferation of endothelial cells in the area of trauma after the vascular tubular walls have been traumatized, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof to the animal to inhibit the narrowing of the vascular tubular walls by the proliferation of endothelial cells into the area of trauma.

Abstract: A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology or trauma of skin or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeutically effective non-toxic dosage amount of a drug for the treatment of the disease or condition of the skin or exposed tissue at the site of the pathology or trauma and an effective non-toxic dosage amount of hyaluronic acid or salts thereof or homologues, analogues, derivatives, complexes, esters, fragments, or sub-units of hyaluronic acid to transport the drug to the site of the pathology or trauma of the disease or condition.

Abstract: The invention relates to a method of controlling the unloading of a drug from the skin or exposed tissue of a human into the lymphatic system comprising transporting an effective dosage amount of the drug into the skin or exposed tissue by an effective non-toxic amount of a form of hyaluronic acid.

Abstract: Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue of a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue of a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.

Abstract: A method for the treatment of mucous membrane trauma disease or condition for the relief of pain associated therewith comprising administering topically an effective amount of a composition comprising an N.S.A.I.D. and a form of hyaluronic acid selected from hyaluronic acid, pharmaceutically acceptable salts thereof, fragments thereof and/or subunits thereof.

Abstract: A pharmaceutical composition is provided comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology and/or trauma of skin and/or exposed tissue of a human patient in need of treatment suffering from a disease or condition. Each such dosage amount comprises a therapeutically effective non-toxic (to the patient) dosage amount of a drug for the treatment of the disease and/or condition of the skin and/or exposed tissue at the site of the pathology and/or trauma and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof to transport (to facilitate or cause the transport of) the drug to the site of the pathology and/or trauma of the disease or condition.

Abstract: Topically applied transdermally quick penetrating compositions containing a drug and hyaluronic acid and/or salts thereof and methods of treating diseases and conditions employing said compositions.

Abstract: A topically applied transdermally penetrating systemic independent acting pharmaceutical combination and formulation for the treatment of a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective non-toxic amount of a drug which inhibits prostaglandin synthesis administered with, or carried in, an amount of hyaluronic acid and/or salts thereof and/or homologues, analogue

Abstract: A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology and/or trauma of skin and/or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeautically effective non-toxic (to the patient) dosage amount of a drug for the treatment of the disease and/or condition of the skin and/or exposed tissue at the site of the pathology and/or trauma and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid to transport (to facilitate or cause the transport of) the drug to the site of the pathology and/or trauma of the disease or condition.

Abstract: The use of:(a) a non-steroidal anti-inflammatory agent,and(b) hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid,in the manufacture of a pharmaceutical composition for inhibiting, controlling and/or regressing angiogenesis in a therapy wherein dosage amounts taken from the composition each comprise:(1) a therapeutically effective amount of component (a); and(2) a therapeutically effective amount of the hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, the pharmaceutical composition being characterized in that for each dosage amount taken from the pharmaceutical composition, the amount of components (a) and (b) inhibit, control and/or regress angiogenesis.

Abstract: A method is provided of preventing arterial restenosis of an animal after the arteries have been traumatized. The method comprises the administration of a therapeutically effective non-toxic amount of hyaluronic acid and/or pharmaceutically acceptable salts thereof to the animal to prevent narrowing of the arteries. The form of hyaluronic acid is selected from hyaluronic acid and pharmaceutically acceptable salts thereof having a molecular weight less than 750,000 daltons.

Abstract: A method of treating pain topically, said method comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage amount comprising (1) a non-steroidal anti-inflammatory drug (NSAID) in a therapeutically effective amount to treat pain of the skin or exposed tissue and (2) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, its non-toxic salts and combination thereof being between 1% and 3% by weight of the composition, characterized in that said dosage amount of said composition is in a dosage form suitable for topical application to the skin or exposed tissue and in a dosage amount in which component (2) exceeds 10 mg/cm.sup.

Abstract: A method of clearing atherosclerosis comprising the step of administering to a patient, at least one dosage amount of a pharmaceutical composition comprising an effective non-toxic amount of each of a chelating agent, a non-steroidal anti-inflammatory drug (NSAID), an anti-oxidant and a form of hyaluronic acid, selected from hyaluronic acid, salts thereof, homologues, analogues, derivatives, esters, complexes, fragments and subunits.

Abstract: A topically administrable pharmaceutical composition is disclosed which comprises a therapeutically effective amount of a drug which inhibits prostaglandin synthesis, and an amount of a form of hyaluronic acid sufficient to transport the composition through the skin into the epidermis or dermis where the composition remains until discharged via the lymphatic system, wherein(a) the drug is 1-5% by weight of the composition, and(b) the form of hyaluronic acid is 1-3% by weight of the composition, has a molecular weight greater than about 150,000 daltons and less than 750,000 daltons, and is selected from the group consisting of hyaluronic acid and salts thereof.

Abstract: A method of treating a human having a disease or condition characterized by macrophage, neutrophile or other white blood cell infiltration into the area damaged by the disease or condition, the method comprising administering to the human an effective amount of hyaluronic acid and/or salts thereof for a period of time until the administration is no longer required.